Luminopia

United States - Cambridge, Massachusetts

• 29/06/2023
• Series A
• $16,000,000

Luminopia is pioneering a new class of treatments for significant neuro-visual disorders. Luminopia is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients. As an Innovation Partner of Boston Children’s Hospital, the company is developing its lead product to treat amblyopia, the leading cause of vision loss among children. For more information, visit luminopia.com.

Related People

Scott XiaoCo Founder

United States - Cambridge, Massachusetts

Digital health founder, MIT Tech Review 35 Innovators Under 35, and Forbes 30 Under 30 recipient.

Currently building Luminopia, to pioneer a new class of medicines for neuro-visual disorders. We're starting with amblyopia (or lazy eye), the leading cause of vision loss in children. Instead of asking kids to wear an eye-patch, our technology turns popular TV shows into treatment, by presenting content slightly differently to each eye using a virtual reality headset. We've shown safety and efficacy in almost 200 patients across several clinical trials, and we recently received the first FDA approval of a VR-based therapeutic for any medical condition.

LinkedIn https://www.linkedin.com/in/xiaoscott/